|Day Low/High||117.51 / 121.99|
|52 Wk Low/High||113.52 / 165.66|
The public market is currently divorced from the dazzling IPOs -- and that's always a bad sign.
Jazz Pharmaceuticals was a winner within the health care sector, rising $3.76 (2.5%) to $155.24 on average volume
Stocks with insider trader activity include IP, CYBX and JAZZ
TheStreet highlights 3 stocks pushing the drugs industry lower today.
Jazz Pharmaceuticals was a leading decliner within the health care sector, falling $12.92 (-7.4%) to $162.06 on heavy volume
Trade-Ideas LLC identified Jazz Pharmaceuticals (JAZZ) as a post-market laggard candidate
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Jazz Pharmaceuticals plc was identified as having a larger market cap than the smaller end of the S&P 500, for example Waters Corp. , according to The Online Investor.
Stocks with insider trader activity include MJN, JAZZ and CLB
Over the past five years, Jazz Pharmaceuticals has grown an average of 175% a year.
IBM is a sell and Ethan Allen is poised for gains this year.
Investors need to sit tight and wait before starting to pick through the rubble, Cramer says.
Hint: It's about Ireland. And Taxes. Lower U.S. Taxes.
Trade-Ideas LLC identified Jazz Pharmaceuticals (JAZZ) as a "perilous reversal" (up big yesterday but down big today) candidate
Jazz Pharmaceuticals was a leading decliner within the health care sector, falling $1.75 (-1.3%) to $136.07 on average volume
After a big 2013 sector rally, Robert Freedland looks ahead to next year.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.